Psilocybin therapy in the UK is only available inside approved clinical trials, because psilocybin is a Class A drug under the Misuse of Drugs Act 1971 and sits in Schedule 1 of the Misuse of Drugs Regulations 2001. Schedule 1 is the tightest category: substances there are treated as having no recognized medical use, and researchers need a special Home Office license to hold them at all.
That does not mean nothing is happening. Some of the most cited psilocybin research of the last decade came out of British universities, and the gap between what the science suggests and what the law allows is the reason this topic keeps coming back.
What psilocybin therapy actually involves
In research settings, psilocybin therapy is not simply taking mushrooms. A typical trial protocol has three parts. First come preparation sessions, where a participant meets the therapists who will be in the room, talks through intentions and fears, and learns what the experience may feel like. Then comes the dosing session itself, usually six to eight hours in a quiet room with two trained facilitators, eyeshades and a set music playlist. Last come integration sessions in the days and weeks after, where the participant makes sense of what came up.
The drug is given as a measured dose of synthetic psilocybin, not as dried mushrooms, so the amount is known exactly. Participants are screened before they are accepted, and people with a personal or family history of psychosis or bipolar disorder are normally excluded.
What the UK research has found so far
Imperial College London opened its Centre for Psychedelic Research in 2019, the first center of its kind, and its team has run several of the trials that shaped the field. In 2021 the New England Journal of Medicine published an Imperial trial that compared psilocybin with escitalopram, a common antidepressant, in 59 people with moderate to severe depression. On the main measure the two groups did not differ by a statistically significant margin, though several secondary measures favored psilocybin. The authors were clear that larger and longer trials were needed.
A year later the same journal published a larger trial run by the London company Compass Pathways. It tested its psilocybin formulation, COMP360, in 233 people with treatment-resistant depression across ten countries. A single 25 mg dose, given with psychological support, reduced depression scores more than a 1 mg dose at three weeks. Side effects such as headache and nausea were common, and some participants in every group reported suicidal thoughts or self-harm, which is one reason the field moves slowly.
The fair reading of the evidence today is that psilocybin with structured support looks promising for depression, that results vary a lot from person to person, and that nobody yet knows how long the benefits last for most people.
Where psilocybin therapy is legal outside the UK
People in Britain who want a supervised psilocybin experience often look abroad. The rules differ more than most retreat websites admit:
- The Netherlands banned fresh and dried magic mushrooms in 2008, but psilocybin truffles, the underground part of the fungus, were left out of the ban. Truffle retreats operate openly.
- Portugal decriminalized personal possession of all drugs in 2001. That is not the same as legalization: possession is still an offense dealt with outside the criminal courts, and there is no legal supply.
- Jamaica does not list psilocybin mushrooms in its drug laws, and a number of retreat centers run there.
- Oregon voted for Measure 109 in 2020 and opened licensed psilocybin service centers in 2023. Clients do not need a diagnosis or a prescription.
- Colorado passed Proposition 122 in 2022, and the state began licensing healing centers for supervised psilocybin sessions in 2025.
- Australia allowed authorized psychiatrists to prescribe psilocybin for treatment-resistant depression from 1 July 2023, the first country to do so at a national level.
Legal status says nothing about quality. A legal retreat can still have untrained staff, poor screening and no plan for a participant who has a difficult time. Before booking anywhere, ask who does the medical screening, how many facilitators are present per guest, what happens if someone needs a doctor during the night, and what support exists after you fly home.
Who should not take psilocybin
Trials exclude some people from taking psilocybin for good reasons, and the same reasons apply outside a trial. A personal or family history of psychosis, schizophrenia or bipolar disorder is the clearest one. Heart conditions matter because psilocybin raises blood pressure and heart rate for several hours. Some medicines interact badly: lithium taken with classic psychedelics has been linked to seizures in an analysis of user reports published in 2021, and antidepressants such as SSRIs can blunt or change the effects. Anyone on regular medication should talk to their doctor before going anywhere near a retreat, and should never stop a medicine on their own to make room for one.
Will the UK change the law?
The UK may change the law in time, and there have been repeated calls, from researchers and from some members of Parliament, to move psilocybin from Schedule 1 to Schedule 2 so that research becomes cheaper and easier to run. Moving it would not make psilocybin therapy available on the NHS. It would only lower the barrier for scientists. Any route to licensed treatment would still run through the medicines regulator, the MHRA, and through trials large enough to answer the open questions about safety and lasting benefit.
For now, the honest answer for anyone in the UK is that the legal options are joining a clinical trial, traveling to a place where psilocybin sessions are allowed, or waiting. Our guide to psychedelic integration covers what helps after an experience, wherever it happens.
